Free Essay

Personalized Medicine Diagnostics Market

In: Business and Management

Submitted By rajivshah
Words 3516
Pages 15
Renub Research www.renub.com Personalized Medicine Diagnostics (Flow Cytometry, Sepsis Immunos, Routine Coagulation, Psychiatric Disorders, Tumor Markers, Molecular Blood Typing and Other Testing) Market & Forecast

Published: June, 2013
Copyright © 2013 Renub Research – All Rights Reserved

Personalized Medicine - Market Overview
Personalized Medicine is often defined as “the right treatment for the right person at the right time.” Personalized medicine is becoming the place to be in clinical diagnostics as well and slowly becoming the reality of future in the diagnostics industry By Technology Segment - Personalized Medicine diagnostics market is expected to grow with a double digit CAGR for the period of 2013 to 2018. It is expected that personalized medicine diagnostics market by technology is going to double by 2018 from its current market size in 2012. In this segment, Point of Care Testing and Molecular Diagnostics segments control the #1 and #2 positions in 2012. By Diseases Segment - Personalized Medicine diagnostics market is expected to be more than US$ 30 Billion by 2018. Diabetes management test and Cancer management test are the leading market in this segment. Renub Research report entitled “Personalized Medicine Diagnostics (Flow Cytometry, Sepsis Immunos, Routine Coagulation, Psychiatric Disorders, Tumor Markers, Molecular Blood Typing and Other Testing)” report provides a comprehensive analysis of the emerging personalized medicine diagnostic market segments, including their dynamics, size, market share, key investors, clinical trials statement, technological trends, company analysis and a realistic future potential for personalized medicine in clinical testing. The report also entails major drivers and challenges of personalized medicine diagnostic market. This 173 page report contains 94 Figures and 16 Tables studies the Personalized Medicine Diagnostics Market. This report contains 12 chapters   Chapter 1 is Executive Summary Chapter 2 contains worldwide personalized medicine diagnostic market & forecast (2011 – 2018). The market includes technological & disease-wise personalized medicine diagnostics market  Chapter 3 contains worldwide personalized medicine diagnostic market share segment. Segment include Technology, Disease-Wise

© Renub Research

Page 2 of 18



Chapter 4 contains segment-wise technological personalized diagnostic market & forecast (2010 - 2018)



Chapter 5 contains geographical segment-wise personalized diagnostic market & forecast (2011 - 2018)



Chapter 6 contains disease-wise personalized diagnostic market share & forecast (2011 - 2018)



Chapter 7 contains disease-wise personalized diagnostic market & forecast (2011 2018)



Chapter 8 and 9 contains clinical trial statement and key investors in Personalized Diagnostics Medicine Market

 

Chapter 10 and 11 contains growth Drivers & Challenges for Personalized Medicine Chapter 12 contains company analysis of Personalized Medicine

Companies analyzed in this report are:      HistoRx A&G Pharmaceuticals Inc 20/20 GeneSystems Tethys Bioscience Genomas Inc

Data Sources This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Renub Research team of industry experts. Primary sources include industry surveys and telephone interviews with industry experts.

© Renub Research

Page 3 of 18

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.

© Renub Research

Page 4 of 18

Table of Contents
1. Executive Summary

2.

Worldwide Personalized Medicine Diagnostic Market & Forecast 2.1 2.2 By Technology – Worldwide Personalized Medicine Diagnostic Market & Forecast By Diseases – Worldwide Personalized Medicine Diagnostic Market & Forecast

3.

Worldwide – Personalized Medicine Diagnostic Market Share Segment 3.1 3.2 By Technology – Worldwide Personalized Medicine Diagnostic Market Share & Forecast By Disease – Worldwide Personalized Medicine Diagnostic Market Share & Forecast

4.

By Technology – Personalized Medicine Diagnostic Market & Forecast 4.1 4.2 4.3 4.4 4.5 4.6 4.7 4.8 Worldwide – Pharmacogenetics Market & Forecast Worldwide – Pharmacogenomics Market & Forecast Worldwide – SNP Genotyping Market & Forecast Worldwide – Pharmacoproteomics Market & Forecast Worldwide – Biochips Market & Forecast Worldwide – Point of Care Test Market & Forecast Worldwide – Molecular Diagnostics Market & Forecast Worldwide – Genetic Screening Market & Forecast

5.

By Geographical Segmentation – Personalized Medicine Diagnostic Market & Forecast 5.1 5.2 North America – Personalized Medicine Diagnostic Market & Forecast Western Europe (EU5) – Personalized Medicine Diagnostic Market & Forecast

6.

By Disease – Personalized Medicine Diagnostic Market Share & Forecast 6.1 6.2 6.3 6.4 Worldwide – Cardiovascular Management Test Market Share & Forecast Worldwide – Diabetes Management Test Market Share & Forecast Worldwide – Coagulation Test Market Share & Forecast Worldwide – Cancer Management Test Market Share & Forecast

© Renub Research

Page 5 of 18

6.5

Worldwide – Infectious Diseases Test Market Share & Forecast

7.

By Disease – Personalized Medicine Diagnostic Market & Forecast 7.1 Worldwide – Cardiovascular Management Test Market & Forecast

7.2

Worldwide – Cardiovascular Management Test Market & Forecast (By Segment) Cardiac Marker Immunoassays Market & Forecast Cardiac Risk Markers Market & Forecast Cardiac Markers Molecular Test Market & Forecast

7.2.1 7.2.2 7.2.3

7.3

Worldwide – Diabetes Management Test Market & Forecast

7.4

Worldwide – Diabetes Management Test Market & Forecast (By Segment) Blood Glucose Monitoring Market & Forecast Hemoglobin A1C (HbA1c) Test Market & Forecast

7.4.1 7.4.2

7.5

Worldwide – Coagulation Test Market & Forecast

7.6

Worldwide – Coagulation Test Market & Forecast (By Segment) Routine Coagulation Test Market & Forecast Molecular Coagulation Test Market & Forecast

7.6.1 7.6.2

7.7

Worldwide – Cancer Management Test Market & Forecast

7.8

Worldwide – Cancer Management Test Market & Forecast (By Segment) Pharmacodiagnostic Histology Test Market & Forecast Flow Cytometry Market & Forecast Tumor Markers Market & Forecast Human Papillomavirus (HPV) Test Market & Forecast Molecular Assays Market & Forecast Circulating Tumor Cells Market & Forecast

7.8.1 7.8.2 7.8.3 7.8.4 7.8.5 7.8.6

7.9

Worldwide – Infectious Diseases Test Market & Forecast

7.10

Worldwide – Infectious Diseases Test Market (By Segment)

© Renub Research

Page 6 of 18

7.10.1 7.10.2 7.10.3 7.10.4 7.10.5 7.10.6 7.10.7

Human Immunodeficiency Virus (HIV) CD4 Count Market & Forecast Human Immunodeficiency Virus (HIV) Viral Load Test Market & Forecast Hepatitis C (HCV) Viral Load Test Market & Forecast Hepatitis B (HBV) Viral Load Test Market & Forecast Hospital Acquired Infections (HAI) Molecular Test Market & Forecast Sepsis Immunos Test Market & Forecast Multi Drug Resistant Tuberculosis (MDR-TB) Test Market & Forecast

7.11

Worldwide – Microbiology Identification/ Antibiotic Sensitivity Test (ID/AST) Market &

Forecast 7.12 7.13 7.14 Worldwide – Psychiatric Disorders Test Market & Forecast Worldwide – Transplant Tissue Typing (HLA) Test Market & Forecast Worldwide – Molecular Blood Typing Market & Forecast

8.

Personalized Medicine Clinical Trial Statement 8.1 8.2 Biomarker Research for Personalized Medicine in Blood Cancer Patient Genetic & Environmental Determinants of Immune Phenotype Variance: Establishing a Path

towards Personalized Medicine 8.3 Warfarin Adverse Event Reduction for Adults Receiving Genetic Testing at Therapy Initiation

(WARFARIN) 8.4 8.5 8.6 Genetic Analysis for Personalized Medicine for Morbid Obesity Pharmacogenomics for Antidepressant Guidance & Education I-SPY 2 Trial (Investigation of Serial Studies to Predict your Therapeutic Response with

Imaging & Molecular Analysis) 8.7 8.8 8.9 8.10 Genetic Mechanisms in Human Hypertension RAAS Inhibition Study Open Label Study for the Functional Characterization of Drug Metabolism and Transport Personalized Therapy in Non-Small Cell Lung Cancer A Pilot Study of Personalized Medicine for Pediatric Asthma

9.

Key Investors in Personalized Medicine Market

10. 10.1

Key Drivers (Opportunities) of Growth in Personalized Medicine Diagnostic Market Government Agencies Shaping Personalized Medicine Diagnostic Market

© Renub Research

Page 7 of 18

10.2 10.3

Organizations will Profit Together, Not Alone in the Personalized Medicine The Blockbuster Model of One Drug Fits all is under Pressure

11. 11.1 11.2 11.3

Challenges in Personalized Medicine Diagnostic Market Reimbursement Policy & Regulatory Framework Regulatory Framework Payers Worry That Cost of Personalized Medicine Could Be Unsustainable

12. 12.1

Company Analysis HistoRx Focus/Market Served Outlook/ Strategy for Success Products

12.1.1 12.1.2 12.1.3

12.2

A&G Pharmaceutical, Inc Focus/Market Served Outlook/Strategy for Success Products

12.2.1 12.2.2 12.2.3

12.3

20/20 GeneSystems Focus/Market Served Outlook/Strategy for Success Products

12.3.1 12.3.2 12.3.3

12.4

Tethys Bioscience Focus/Market Served Outlook/Strategy for Success Products

12.4.1 12.4.2 12.4.3

12.5

Genomas, Inc. Focus/Market Served Products

12.5.1 12.5.2

© Renub Research

Page 8 of 18

List of Figures

Figure 2-1: Worldwide – By Technology Personalized Medicine Diagnostic Market (Million US$), 2010 – 2012 Figure 2-2: Worldwide – Forecast for By Technology Personalized Medicine Diagnostic Market (Million US$), 2013 – 2018 Figure 2-3: Worldwide – By Diseases Personalized Medicine Diagnostic Market (Million US$), 2011 – 2012 Figure 2-4: Worldwide – Forecast for By Diseases Personalized Medicine Diagnostic Market (Million US$), 2013 – 2018

Figure 3-1: Worldwide – By Technology Personalized Medicine Diagnostic Market Share (Percent), 2010 – 2012 Figure 3-2: Worldwide – Forecast for By Technology Personalized Medicine Diagnostic Market Share (Percent), 2013 – 2018

Figure 4-1: Worldwide – Pharmacogenetics Market (Million US$), 2010 – 2012 Figure 4-2: Worldwide – Forecast for Pharmacogenetics Market (Million US$), 2013 – 2018 Figure 4-3: Worldwide – Pharmacogenomics Market (Million US$), 2010 – 2012 Figure 4-4: Worldwide – Forecast for Pharmacogenomics Market (Million US$), 2013 – 2018 Figure 4-5: Worldwide – SNP Genotyping Market (Million US$), 2010 – 2012 Figure 4-6: Worldwide – Forecast for SNP Genotyping Market (Million US$), 2013 – 2018 Figure 4-7: Worldwide – Pharmacoproteomics Market (Million US$), 2010 – 2012 Figure 4-8: Worldwide – Forecast for Pharmacoproteomics Market (Million US$), 2013 – 2018 Figure 4-9: Worldwide – Biochips Market (Million US$), 2010 – 2012 Figure 4-10: Worldwide – Forecast for Biochips Market (Million US$), 2013 – 2018 Figure 4-11: Worldwide – Point of Care Testing Market (Million US$), 2009 – 2012 Figure 4-12: Worldwide – Forecast for Point of Care Testing Market (Million US$), 2013 – 2018 Figure 4-13: Worldwide – Molecular Diagnostics Market (Million US$), 2010 – 2012 Figure 4-14: Worldwide – Forecast for Molecular Diagnostics Market (Million US$), 2013 – 2018 Figure 4-15: Worldwide – Genetic Screening Market (Million US$), 2010 – 2012 Figure 4-16: Worldwide – Forecast for Genetic Screening Market (Million US$), 2013 – 2018

Figure 5-1: North America – Personalized Medicine Diagnostic Market (Million US$), 2011 – 2012 Figure 5-2: North America – Forecast for Personalized Medicine Diagnostic Market (Million US$), 2013 – 2018 Figure 5-3: Western Europe (EU-5) – Personalized Medicine Diagnostic Market (Million US$), 2011 – 2012

© Renub Research

Page 9 of 18

Figure 5-4: Western Europe (EU-5) – Forecast for Personalized Medicine Diagnostic Market (Million US$), 2013 – 2018

Figure 6-1: Worldwide – Cardiovascular Management Test Market Share (Percent), 2011 – 2012 Figure 6-2: Worldwide – Forecast for Cardiovascular Management Test Market Share (Percent), 2013 – 2018 Figure 6-3: Worldwide – Diabetes Management Test Market Share (Percent), 2011 – 2012 Figure 6-4: Worldwide – Forecast for Diabetes Management Test Market Share (Percent), 2013 – 2018 Figure 6-5: Worldwide – Coagulation Test Market Share (Percent), 2011 – 2012 Figure 6-6: Worldwide – Forecast for Coagulation Test Market Share (Percent), 2013 – 2018 Figure 6-7: Worldwide – Cancer Management Test Market Share (Percent), 2011 – 2012 Figure 6-8: Worldwide – Forecast for Cancer Management Test Market Share (Percent), 2013 – 2018 Figure 6-9: Worldwide – Infectious Diseases Test Market Share (Percent), 2011 – 2012 Figure 6-10: Worldwide – Forecast for Infectious Diseases Test Market Share (Percent), 2013 – 2018

Figure 7-1: Worldwide – Cardiovascular Management Test Market (Million US$), 2011 – 2012 Figure 7-2: Worldwide – Forecast for Cardiovascular Management Test Market (Million US$), 2013 – 2018 Figure 7-3: Worldwide – Cardiac Marker Immunoassays Market (Million US$), 2011 – 2012 Figure 7-4: Worldwide – Forecast for Cardiac Marker Immunoassays Market (Million US$), 2013 – 2018 Figure 7-5: Worldwide – Cardiac Risk Markers Market (Million US$), 2011 – 2012 Figure 7-6: Worldwide – Forecast for Cardiac Risk Markers Market (Million US$), 2013 – 2018 Figure 7-7: Worldwide – Cardiac Markers Molecular Test Market (Million US$), 2011 – 2012 Figure 7-8: Worldwide – Forecast for Cardiac Markers Molecular Test Market (Million US$), 2013 – 2018 Figure 7-9: Worldwide – Diabetes Management Test Market (Million US$), 2011 – 2012 Figure 7-10: Worldwide – Forecast for Diabetes Management Test Market (Million US$), 2013 – 2018 Figure 7-11: Worldwide – Blood Glucose Monitoring Market (Million US$), 2011 – 2012 Figure 7-12: Worldwide – Forecast for Blood Glucose Monitoring Market (Million US$), 2013 – 2018 Figure 7-13: Worldwide – Hemoglobin A1C (HbA1c) Test Market (Million US$), 2011 – 2012 Figure 7-14: Worldwide – Forecast for Hemoglobin A1C (HbA1c) Test Market (Million US$), 2013 – 2018 Figure 7-15: Worldwide – Coagulation Test Market (Million US$), 2011 – 2012 Figure 7-16: Worldwide – Forecast for Coagulation Test Market (Million US$), 2013 – 2018 Figure 7-17: Worldwide – Routine Coagulation Test Market (Million US$), 2011 – 2012 Figure 7-18: Worldwide – Forecast for Routine Coagulation Test Market (Million US$), 2013 – 2018 Figure 7-19: Worldwide – Molecular Coagulation Test Market (Million US$), 2011 – 2012 Figure 7-20: Worldwide – Forecast for Molecular Coagulation Test Market (Million US$), 2013 – 2018 Figure 7-21: Worldwide – Cancer Management Test Market (Million US$), 2011 – 2012

© Renub Research

Page 10 of 18

Figure 7-22: Worldwide – Forecast for Cancer Management Test Market (Million US$), 2013 – 2018 Figure 7-23: Worldwide – Pharmacognostic Histology Test Market (Million US$), 2011 – 2012 Figure 7-24: Worldwide – Forecast for Pharmacognostic Histology Test Market (Million US$), 2013 – 2018 Figure 7-25: Worldwide – Flow Cytometry Market (Million US$), 2011 – 2012 Figure 7-26: Worldwide – Forecast for Flow Cytometry Market (Million US$), 2013 – 2018 Figure 7-27: Worldwide – Tumor Markers Market (Million US$), 2011 – 2012 Figure 7-28: Worldwide – Forecast for Tumor Markers Market (Million US$), 2013 – 2018 Figure 7-29: Worldwide – Human Papillomavirus (HPV) Test Market (Million US$), 2011 – 2012 Figure 7-30: Worldwide – Forecast for Human Papillomavirus (HPV) Test Market (Million US$), 2013 – 2018 Figure 7-31: Worldwide – Molecular Assays Market (Million US$), 2011 – 2012 Figure 7-32: Worldwide – Forecast for Molecular Assays Market (Million US$), 2013 – 2018 Figure 7-33: Worldwide – Circulating Tumor Cells Market (Million US$), 2011 – 2012 Figure 7-34: Worldwide – Forecast for Circulating Tumor Cells Market (Million US$), 2013 – 2018 Figure 7-35: Worldwide – Infectious Diseases Test Market (Million US$), 2011 – 2012 Figure 7-36: Worldwide – Forecast for Infectious Diseases Test Market (Million US$), 2013 – 2018 Figure 7-37: Worldwide – HIV CD4 Count Market (Million US$), 2011 – 2012 Figure 7-38: Worldwide – Forecast for HIV CD4 Count Market (Million US$), 2013 – 2018 Figure 7-39: Worldwide – HIV Viral Load Test Market (Million US$), 2011 – 2012 Figure 7-40: Worldwide – Forecast for HIV Viral Load Test Market (Million US$), 2013 – 2018 Figure 7-41: Worldwide – HCV Viral Load Test Market (Million US$), 2011 – 2012 Figure 7-42: Worldwide – Forecast for HCV Viral Load Test Market (Million US$), 2013 – 2018 Figure 7-43: Worldwide – HBV Viral Load Test Market (Million US$), 2011 – 2012 Figure 7-44: Worldwide – Forecast for HBV Viral Load Test Market (Million US$), 2013 – 2018 Figure 7-45: Worldwide – HAI Molecular Test Market (Million US$), 2011 – 2012 Figure 7-46: Worldwide – Forecast for HAI Molecular Test Market (Million US$), 2013 – 2018 Figure 7-47: Worldwide – Sepsis Immunos Test Market (Million US$), 2011 – 2012 Figure 7-48: Worldwide – Forecast for Sepsis Immunos Test Market (Million US$), 2013 – 2018 Figure 7-49: Worldwide – Multi Drug Resistant Tuberculosis (MDR-TB) Market (Million US$), 2011 – 2012 Figure 7-50: Worldwide – Forecast for Multi Drug Resistant Tuberculosis (MDR-TB) Market (Million US$), 2013 – 2018 Figure 7-51: Worldwide – Microbiology ID/AST Market (Million US$), 2011 – 2012 Figure 7-52: Worldwide – Forecast for Microbiology ID/AST Market (Million US$), 2013 – 2018 Figure 7-53: Worldwide – Psychiatric Disorders Test Market (Million US$), 2011 – 2012 Figure 7-54: Worldwide – Forecast for Psychiatric Disorders Test Market (Million US$), 2013 – 2018 Figure 7-55: Worldwide – Transplant Tissue Typing (HLA) Test Market (Million US$), 2011 – 2012 Figure 7-56: Worldwide – Forecast for Transplant Tissue Typing (HLA) Test Market (Million US$), 2013 – 2018

© Renub Research

Page 11 of 18

Figure 7-57: Worldwide – Molecular Blood Typing Market (Million US$), 2011 – 2012 Figure 7-58: Worldwide – Forecast for Molecular Blood Typing Market (Million US$), 2013 – 2018

© Renub Research

Page 12 of 18

List of Tables

Table 3-1: Worldwide – By Diseases Personalized Medicine Diagnostic Market Share (Percent), 2011 – 2012 Table 3-2: Worldwide – Forecast for By Diseases Personalized Medicine Diagnostic Market Share (Percent), 2013 – 2018

Table 7-1: Selected Human Papillomavirus (HPV) Tests, 2011 Table 7-2: Selected Molecular Personalized Medicine Tests in Cancer, 2011

Table 8-1: Clinical Trial – Biomarker Research for Personalized Medicine in Blood Cancer Patient Table 8-2: Clinical Trial – Genetic & Environmental Determinants of Immune Phenotype Variance: Establishing a Path Towards Personalized Medicine Table 8-3: Clinical Trial – Warfarin Adverse Event Reduction for Adults Receiving Genetic Testing at Therapy Initiation Table 8-4: Clinical Trial – Genetic Analysis for Personalized Medicine for Morbid Obesity Table 8-5: Clinical Trial – Pharmacogenomics for Antidepressant Guidance & Education Table 8-6: Clinical Trial – I-SPY 2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging & molecular Analysis) Table 8-7: Clinical Trial – Genetic Mechanisms in Human Hypertension RAAS Inhibition Study Table 8-8: Clinical Trial – Open Label Study for the Functional Characterization of Drug Metabolism and Transport Table 8-9: Clinical Trial – Personalized Therapy in Non-small Cell Lung Cancer Table 8-10: Clinical Trial – A Pilot Study of Personalized Medicine for Pediatric Asthma

Table 9-1: Key Investors in Personalized Medicine, 2011 & 2012

Table 12-1: Partnership & Alliance Models in Personalized Medicine

© Renub Research

Page 13 of 18

Related Reports
Molecular Diagnostics Market & Forecast (By Application, Technology, Countries, Companies & Clinical Trials) to 2017: Global Analysis Point of Care Testing Market and Forecast to 2016: Global Analysis Pediatric Vaccines Market, Doses, Immunization, Cases and Forecast: Worldwide Analysis Western Europe (EU-16) In Vitro Diagnostics Market Report & Forecast (2012 – 2015) Asia Medical Tourism Analysis and Forecast to 2015 Clinical Chemistry Market Report & Forecast (2012 – 2015): Global Analysis Hepatitis C (HCV) Market Forecast & Drugs Pipeline Analysis to 2016 Influenza Vaccine Market Opportunities and Challenges: Worldwide Forecast Genetic Testing Market and Forecast - Global Analysis 2010 – 2015 USA Cardiovascular Devices Market Trends and Forecast (2010 – 2015) Global Osteoporosis Market & Drugs Analysis 2010 – 2015 Global Schizophrenia Prevalence, Companies Analysis & Drugs Forecast (2010 – 2015) Global Molecular Diagnostics Market & Future Forecast 2010 - 2014 Alzheimer’s Disease Patients & Market Worldwide, Future Scenario (2010 – 2015) & Drugs Analysis Global Cardiovascular Surgery Devices Market Trends and Future Forecast (2009 – 2014)

© Renub Research

Page 14 of 18

Our Partial List of Clients

Redbus Becton Dickinson Pfizer Intercell Sanofi Pasteur Stanford Burgess Pequot Capital DMI Transgene S.A. ixia communications Toyota Tsusho Amercia Inc. National Health Research Institutes Abbott Diabetes Care Corning Incorporated - Life Sciences L.E.K. Consulting GmbH Syntiron MediVas LLC Credit Suisse Dune Medical QIAGEN Inje University Mapp Biopharmaceutical Institute for Information Industry NorDiag ASA Rep e Inv Medicas SA de Innogenetics © Renub Research

Bain WAKE Technology Services, Inc. PSS World Medical Relypsa C&K components Konkuk University Resonetics Samsung SEKISUI MEDICAL CO. LTD. Plentyoffish Media INC Arthur D Little Gmbh Morgan Stanley Takeda Pharmaceutical Corporation Hokkai School of Commerce Ministry of Manpower Singapore GenOmind, LLC. Goldman Sachs & Co NTT Advanced Technology Tokyo Womens Medical University The Chemo-Sero-Therapeutic Research Trade Council of Iceland Jpmorgan, Ets Trading GE Healthcare IT ixia communications

Page 15 of 18

Order Form
Scan and e-mail this page to info@renub.com, alternatively one can also write the Contact Information in an e-mail and mail it. Else you can also fax this form to +91-120-424-9780 Questions? Please call +91-120-421-9822 (India), +1-678-302-0700 (USA) or mail to info@renub.com

Format
Report Title: Personalized Medicine Diagnostics (Flow Cytometry, Sepsis Immunos, Routine Coagulation, Psychiatric Disorders, Tumor Markers, Molecular Blood Typing and Other Testing)

Single User (Email from Publisher) US$ 1,400

Hard Copy (Mail Delivery) US$ 1,550

CD – Rom (Mail Delivery) US$ 1,500

Global Site License (Multiple User License) US$ 2,200

For ordering this report: Three easy ways to place your order:
1) Order online by Credit Card (Visa, MasterCard, etc.): http://www.renub.com/report/personalized-medicine-diagnostics-flow-cytometry-sepsisimmunos-routine-coagulation-psychiatric-disorders-tumor-markers-molecular-blood-typingand-other-testing-116 2) Order by Wire Transfer: http://www.renub.com/report/wiretransfer.aspx?id=116&pid=1449 To pay by Wire Transfer, please, fill in your contact details in the form below:

© Renub Research

Page 16 of 18

Bank Details
Account Name: Renub Research A/C No.: 109102000023296 Name of Bank: IDBI Bank Ltd. Swift Code: IBKLINBB010 Bank Address: 4th Floor Indian Red Cross Building 1 Red Cross Road Opposite Parliament Street New Delhi – 110001 India

Contact Information
First Name: Email: Job Title: Company: Address: City: Postal/Zip Code: Country: Phone: Mobile: Fax: Report Format: Your message: Last Name:

© Renub Research

Page 17 of 18

3) Order by Check Please post the check accompanied by this form, to: Company Address: Renub Research 1St Floor C-86, Sector -10 Noida - 201301 Uttar Pradesh India Phone: +91-120-421-9822, 424-9780

For free Sample copy report or to view any of our sample work please contact us at info@renub.com or call +91-120-421-9822 (India), +1-678-302-0700 (USA)

Follow Us
Facebook: http://www.facebook.com/pages/Renub-Research/233380966701090 LinkedIn: http://www.linkedin.com/company/renub-research Twitter: http://twitter.com/RenubResearch

© Renub Research

Page 18 of 18

Similar Documents

Free Essay

Personalized Medicine

...Wuanda S Green Introduction to Biology Dr. Russell Barnett Personalized Medicine Personalized medicine is a new field of healthcare that is based on an individual’s unique genetic, genomic, clinical and environmental information. The factors vary from one person to another just like the onset of diseases so the purpose of personalized medicine is to react to the individual’s symptoms in the way, with personalized treatment (Jain, 2007). Personalized medicine primary goal and target is to make a treatment as individualize as the person receiving the treatment. This method involves identifying genetic, genomic, and clinical information that will allow accurate predictions to be made about an individual’s susceptibility to a developing disease, the course of that disease and the response to treatment (Cohen, 2008). Modern genetic technology started with the genome project which leads to the benefits and development of personalized medicine (Cohen, 2008). The human genome is the blueprint for each person's body, influencing how we look, our genetic predispositions for certain medical conditions, how well our bodies fight disease or metabolize food, and which therapies our bodies do and do not respond to (Hart, 2005). The genome consists of an organism's total DNA, including its genes. DNA—the famous "double helix"—is composed of four chemicals, which are repeated many times in different sequences (Jain, 2007). (The names of the chemicals are abbreviated as A, T, C, and G.......

Words: 751 - Pages: 4

Premium Essay

Gems Case

...and Disease Management Systems make personalized medicine and personalized diagnostics possible. Moreover, healthcare practice move from cure to prevention. These changes require expertise in biomedical sciences rather than in engineering and physics; and also investment, collaboration with pharmaceutical companies which facilitate the creation of imaging equipment necessity to alter GEMS business model which is away from engineering heritage toward bio-chemistry and develop drug based on genetic code for specific individual, or small group rather than entire population. b. Demographic change: + Population were aging in advanced nation, implied fewer working-age people to pay for more intense care while the emerging middle-classes if Asia, Eastern Europe and Latin America were increasingly aware of, and needed, better healthcare. This requires the shift in distribution of healthcare equipment in these countries (more for Asia, Eastern and Latin America) and the change in market segment of healthcare equipment. + Global information flows made healthcare disparities between developed and developing nations more stark and unacceptable. Thus, concentrating more on developing world needs great effort investment and customization. c. Fierce competition: + Siemens is leading in healthcare IT, which is a great advantage for them to thrive in technological change era. All competitors move on healthcare IT segment, potentially affecting the market share of GEMS. 2. Strengths......

Words: 675 - Pages: 3

Premium Essay

Self Test for Operation

... kill thousands of people every day Mosquito-borne diseases hospital-acquired infections 100,000 patients die each year from causes more than 250,000 deaths each year Seasonal flu Medical Model A leap in the evolution of healthcare enabling care providers to deliver the right treatment to the right patient at the right time. 1: IT-enabled Personalized Healthcare 2: Adoption of Electronic Medical Records 3: Disease-Centric to Prevention-Centric NOW CONSUMER CONSUMER FACILITY CONSUMER CONSUMER FUTURE CONSUMER The Digital Hospital Paperless Wireless Long-distance robotic surgery Vivid 7 Cardiovascular Ultrasound System Real time. Real solutions. Real value. VSCAN Pocket-sized, ultra-smart ultrasound Provide an immediate look inside the body Through the Adventure Series, the hospital is working to create fun, soothing care environments for child patients. Medical Model A leap in the evolution of healthcare enabling care providers to deliver the right treatment to the right patient at the right time. 1: IT-enabled Personalized Healthcare 2: Adoption of Electronic Medical Records 3: Disease-Centric to Prevention-Centric One Consistent Problem One of the main reasons illegible lab reports repeat prescription forms & waiting for insurance companies to deny your claims ON THE ST 1 ATTEMPT A large portion of these are...

Words: 669 - Pages: 3

Free Essay

Service Line Development Task 4

...second hospital also has a strong orthopedic program and existing cardiology program. This hospital also has a poorly organized oncology program. Building space for oncology service will allow patients to easily coordinate with services already within the hospital and make use of the newly improved and more developed resources within Trinity Community Hospital. The Community Health Needs Assessment identified that the orthopedic cases are expected to rise by over 46%, inpatient joint and spine procedures by 30%, and outpatient joint and spine procedures by 350% in the next five years. However, there are existing nearby facilities that already cater to this market, some well-renowned. The Needs Assessment also identified, in terms of cardiology services, coronary artery disease is expected to grow over 21%, diagnostic cath procedures by at least 22%, and angioplasties by...

Words: 1375 - Pages: 6

Free Essay

Should Genes Be Patented?

...Should Genes be Patented? Patenting genetic discoveries have proven to be controversial throughout the years. There are now patents that are associated with many of the genes within the human genome. Patents are issued to encourage innovation and protect those investing in genetic research the opportunity to maximize profit. During this period, another party can use the discovery to develop a product only with a licensing agreement; however, basic researchers can use it freely. Some argue that this period of exclusivity fosters commercial development of the discovery by discouraging competition. Yet the patenting of genes is not without controversy. Some reject the entire concept of patenting, while others have objections to the patenting of only specific types of DNA sequences. It has also been argued that patents inhibit or limit biomedical research all together. The patenting of human genetic material raises complex social, ethical, and policy issues such as the potential for discrimination in access to healthcare services or employment, and the implications for ongoing research and access to services. The patentability of inventions concerning human genetic material is determined by the US Patent and Trademark Office (USPTO). To obtain a patent, the invention must meet four criteria. The invention must be “useful” in a practical sense, “novel” (not known or used before filing), “nonobvious” (not an improvement easily made by someone trained in the relevant area), and......

Words: 1603 - Pages: 7

Premium Essay

Opportunities in Healthcare Innovation

...Interpretation Reinterpretation Creativity Spontaneous Induced Challenges Unmet Needs Financial opportunity Entrepreneurship Corporate directives Government Agency directives Competition Crises Fear So What’s Next? Healthcare (Medicine) has to actively adopt Innovation in its teaching and culture, rather than letting it occur passively Innovation is needed to overcome the many stresses that exist on Healthcare (Medicine) today Healthcare Innovation - takes many forms Incremental : Adding a new feature to an existing product Examples: Next generation pacemaker that are safe for MRI, Biodegradable, diagnostic stents Healthcare Innovation - takes many forms Disruptive: New value creation, paradigms change Example: DES, TAVI It is difficult to foresee Disruptive Solutions  They are rare to find: Requires excellent access to the best deal flow and deep intuition about the relevant markets  The validity of their claim is more difficult to substantiate : Requires more thorough due diligence  Development and execution risks are bigger : Needs better team and more focused entrepreneurs This is the ultimate challenge for early stage VCs: Market intuition > Technology validation > People assessment Healthcare Innovation  In healthcare, we’ve innovated new technologies and products  While innovation in service and business models has lagged Core Challenges:  Serve larger populations......

Words: 1244 - Pages: 5

Premium Essay

Point of Care Testing

...means ensuring the right service is efficiently provided at the right time, in the right place, by the most appropriate and least expensive combination of health care providers. One aspect of these emerging trends is Point-of-Care (POC) testing and POC diagnostics. For many years laboratory testing was performed by technologists in a central laboratory. This was necessary because of the complexity of the testing. Computer technology has now taken analysis from the laboratory to the patient’s bedside, the doctor’s office or the patient’s home. This testing is called point-of-care testing (POCT) and is defined as testing at the point where patient care is given, wherever may be. The POCT results are timely, allowing more time for rapid treatment of the patient. It empowers clinicians to make decisions at the “point-of-care” and has the potential to significantly impact health care delivery and address the challenges of health care disparities. The success of this potential shift from curative medicine, to predictive, personalized, and preemptive medicine relies on the development of portable diagnostic and monitoring devices for point-of-care testing. Our parent’s knew point of care testing as it was the way that medicine was delivered in the patient’s home through physician...

Words: 2642 - Pages: 11

Premium Essay

Marketing Strategies

...attempts to make use of the firm’s unique competencies by accepting a portfolio to the business management by developing long term plans. And the middle is the decision-making hierarchy at business-level that translates the statement’s direction and generates corporate-level strategies for business units or SBUs. And the bottom hierarchy is functional-level that develops short term strategies and annual objectives in different areas of organisation. (David, 2003) II. ORGANIZATION & BUSINESS SEGMENTS Company Profile Johnson & Johnson- A most comprehensive health-care firms in the world and most diversified. J&J manufactures health care products for consumer & personal care, pharmaceutical, medical devices and diagnostics markets. It is operating its firms in 57 countries and nearly 200 companies around the world. J&J generates nearly half of its revenues from outside US; through its operating networks and marketing organizations that sells products in 175 countries. (Web 1) Key Facts- Johnson & Johnson Incorporated | 1887, Public Company | Employees | 114,000 | Sales | US $63.7 billion | Net earnings | US $12.9 billion | Stock Exchanges | New York Toronto | Operating locations | 57 Countries | Ticker Symbol | JNJ | Mission- To improve the quality of life for, people at everywhere. Vision- Bringing science to the art of healthy living life. The mission and vision statement shows that J&J gives importance on...

Words: 3826 - Pages: 16

Free Essay

Medical Technology

...decision in retrospect. The life sciences and chemical analysis units now collectively generate half of the company’s sales, and allowed Agilent to remain profitable despite the collapse of the electronic measurement unit’s profits during the financial crisis.  As one of many examples, this illustrates the growing importance of the medtech segment, which is gaining attention of industry groups from various sectors. What factors make medical technology so attractive? Which industries can benefit from expansion into this segment? DEFINITION Segmentation Medical technology is a widely used term but definitions and segmentations aren’t always consistent. Novumed’s comprehensive segmentation of the medical technology market differentiates between diagnostic and therapeutic products and, on the next level, between devices and consumables.  2 Medical...

Words: 3838 - Pages: 16

Premium Essay

Enhancing the Marketing Plan

...roots to offer services such as providing urgent care, daytime, evenings, weekends, holidays, after doctor’s office hour’s convenient and affordable medical services for clients varying from newborns to geriatrics, and respiratory therapy services. These specialized fields act as the backbone of the Patient First, Inc. where its strengths lie, as compared to other organizations. Since the Healthcare Express also has, some of this specialized in house services, Patient First, Inc. gives it tough competition, and clients have to choose between these two competitors when deciding on most of the services and products (Stewart & Hirsch, 2011).. The other strengths for Patient First, Inc. is that the company is dedicated to offering quick, personalized, and courteous treatment in the home. The professional staff are accessible 24 hours a day, 7 days a week ensuring that clients and their caretakers get the services and support required at all times. The staff also treats the patients with utmost care unlike other organizations, which have no time or select patients. This services and concerns, therefore, strengthen Patient First, Inc....

Words: 1702 - Pages: 7

Premium Essay

Concierge Medicine

..."Concierge Medicine, A Solution, Or A Problem?" The landscape for health care delivery has evolved significantly over time. What initiated as a home service by a family physician grew into predominately inpatient service, followed by the expansion of outpatient service. Now, the trend is starting to drift back to a more "family physician" approach with an added cost. Reduced reimbursement rates, increased paperwork, increased operating costs, and increased patient case loads have made it difficult for primary care physicians (PCPs) to be successful compared to their peers. Medicare and Medicaid reimbursement rates continue to be adjusted downward, and PCPs are expected to broaden their practices to compensate. Medical school graduates are choosing careers as specialists for an increased income, stability, set hours, and reduced case loads. As a result, the decline of PCPs has increased resulting in fewer providers coupled with a growing population. Those providers remaining in the PCP field, or deciding to enter that area of service, are looking for new ways to generate revenue and reduce the patient case load. As a result, concierge medicine, also known as boutique medicine, retainer medicine, VIP medicine, executive health program, platinum practice, personalized health care, or luxury health care, has evolved and is currently growing (Harris, 2008). Reasons for the shift in care are continued downward pressure on health plan reimbursement rates both from......

Words: 3016 - Pages: 13

Premium Essay

Pcr Market Research

...2014-2018 Global Polymerase Chain Reaction (PCR) Market EMISPDF us-thermo-url from 208.89.140.11 on 2014-11-24 17:09:41 GMT. DownloadPDF. technavio insights Downloaded by us-thermo-url from 208.89.140.11 at 2014-11-24 17:09:41 GMT. EMIS. Unauthorized Distribution Prohibited. 2014-2018 Global Polymerase Chain Reaction (PCR) Market Table of Contents 01. Executive Summary.......................................... 1 02. List of Abbreviations ......................................... 2 03. Scope of the Report.......................................... 3 03.1 Market Overview .......................................................... 3 03.2 Product Offerings .......................................................... 3 04. Market Research Methodology ..................... 6 04.1 Market Research Process .......................................... 6 04.2 Research Methodology .............................................. 6 05. Introduction ....................................................... 8 06. Market Landscape ........................................... 9 06.1 Market Overview .......................................................... 9 06.2 Market Size and Forecast........................................... 9 06.3 PCR Market in US ........................................................ 10 06.3.1 Mark et Size and Forecast .................................................. 10 06.4 PCR Market in......

Words: 14531 - Pages: 59

Premium Essay

Emerging Patient Driven Health Care Model

...mdpi.com/journal/ijerph Article Emerging Patient-Driven Health Care Models: An Examination of Health Social Networks, Consumer Personalized Medicine and Quantified Self-Tracking Melanie Swan * Research Associate, MS Futures Group, P.O. Box 61258, Palo Alto, CA 94306, USA * Author to whom correspondence should be addressed; E-Mail: m@melanieswan.com; Tel.: +1-415505-4426; Fax: +1-504-910-3803 Received: 9 January 2009 / Accepted: 2 February 2009 / Published: 5 February 2009 Abstract: A new class of patient-driven health care services is emerging to supplement and extend traditional health care delivery models and empower patient self-care. Patient-driven health care can be characterized as having an increased level of information flow, transparency, customization, collaboration and patient choice and responsibility-taking, as well as quantitative, predictive and preventive aspects. The potential exists to both improve traditional health care systems and expand the concept of health care though new services. This paper examines three categories of novel health services: health social networks, consumer personalized medicine and quantified self-tracking. Keywords: Patient-driven health care; health social networks; personalized medicine; quantified self-tracking; health care delivery; predictive health care; preventive health care; long-tail medicine; Internet; open source. 1. Introduction The life sciences field is advancing and changing in nearly every dimension, both......

Words: 14859 - Pages: 60

Premium Essay

Nurse

...developmental outcome in-and-of itself and finally, healthcare spending capitalises on the Keynesian 'economic multiplier' effect. Industry and Global Health The global healthcare industry in the future will be a highly connected environment powered by large data networks, cloud computing, and mobile devices. There will be widespread increases in the number of connected healthcare networks providing seamless integration between care providers, patients, pharmaceutical companies, health insurers, and other invested parties anywhere in the world. Regulatory pressure is being exerted to deliver cost-effective healthcare that produces positive outcomes. Wide-ranging demographic changes are also occurring in this space. For example, emerging markets provide new growth opportunities while an aging population requires a new focus on...

Words: 1387 - Pages: 6

Premium Essay

Jnj Paper

...The Johnson & Johnson vision is to maximize the global power of diversity and inclusion to drive superior business results and a sustainable competitive advantage.   Our Global Diversity and Inclusion Vision Statement, which can be read in its entirety below, identifies our commitment to cultivate a diverse and inclusive culture reflective of our dynamic global marketplace.    The Johnson & Johnson Family of Companies will realize this vision by: * Fostering inclusive cultures that embrace our differences and drive innovation to accelerate growth; * Achieving skilled, high performance workforces that are reflective of the diverse global marketplace; * Working with business leaders to identify and establish targeted market opportunities for consumers across diverse demographic segments; and * Cultivating external relationships with professional, patient and civic groups to support business priorities. The environment is the ultimate human health issue. As the world’s largest health care company, Johnson & Johnson recognizes the critical interdependence between human health and the health of our planet.  We believe a healthy planet and a healthy community go hand in hand. That’s why we are committed to reducing our environmental impacts across all aspects of our operations – striving for performance that does not merely comply with regulations but protects and nurtures the planet’s beauty and resources for future generations.  Guided......

Words: 4280 - Pages: 18